相似文献
1
The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?
J Gastrointest Oncol. 2017 Feb;8(1):189-193. doi: 10.21037/jgo.2016.12.06.
2
How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review.
Cancers (Basel). 2023 Aug 26;15(17):4275. doi: 10.3390/cancers15174275.
3
Neoadjuvant Treatment in Pancreatic Cancer.
Front Oncol. 2020 Feb 28;10:245. doi: 10.3389/fonc.2020.00245. eCollection 2020.
4
Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Front Oncol. 2020 Aug 11;10:1112. doi: 10.3389/fonc.2020.01112. eCollection 2020.
5
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Radiat Oncol. 2019 Jul 10;14(1):120. doi: 10.1186/s13014-019-1330-0.
6
Borderline resectable pancreatic cancer.
Cancer Lett. 2016 Jun 1;375(2):231-237. doi: 10.1016/j.canlet.2016.02.039. Epub 2016 Mar 9.
7
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
BMC Cancer. 2019 Jul 9;19(1):675. doi: 10.1186/s12885-019-5889-5.
8
Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):97-108. doi: 10.14701/ahbps.2019.23.2.97. Epub 2019 May 31.
9
Multimodality management of borderline resectable pancreatic adenocarcinoma.
Chin Clin Oncol. 2017 Jun;6(3):27. doi: 10.21037/cco.2017.06.17.
10
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
引用本文的文献
1
A case report of pancreaticoduodenectomy with en bloc celiac axis resection.
Medicine (Baltimore). 2025 Jul 25;104(30):e42233. doi: 10.1097/MD.0000000000042233.
2
Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.
Indian J Surg Oncol. 2024 May;15(Suppl 2):249-254. doi: 10.1007/s13193-021-01361-1. Epub 2021 Jul 1.
3
CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Status and Perspective on the Use of Radiomics.
J Clin Med. 2023 Oct 29;12(21):6821. doi: 10.3390/jcm12216821.
4
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29.
5
Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis.
J Clin Med. 2021 Jun 19;10(12):2711. doi: 10.3390/jcm10122711.
6
Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
World J Gastroenterol. 2021 Jun 14;27(22):3037-3049. doi: 10.3748/wjg.v27.i22.3037.
7
Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
Cancers (Basel). 2021 Apr 20;13(8):1971. doi: 10.3390/cancers13081971.
本文引用的文献
1
Justifying vein resection with pancreatoduodenectomy - Author's reply.
Lancet Oncol. 2016 May;17(5):e178. doi: 10.1016/S1470-2045(16)30036-5. Epub 2016 Apr 27.
2
Justifying vein resection with pancreatoduodenectomy.
Lancet Oncol. 2016 May;17(5):e177-8. doi: 10.1016/S1470-2045(16)30037-7. Epub 2016 Apr 27.
3
Justifying vein resection with pancreatoduodenectomy.
Lancet Oncol. 2016 Mar;17(3):e118-e124. doi: 10.1016/S1470-2045(15)00463-5. Epub 2016 Mar 2.
4
Genomic analyses identify molecular subtypes of pancreatic cancer.
Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.
5
Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.
World J Clin Oncol. 2016 Feb 10;7(1):27-43. doi: 10.5306/wjco.v7.i1.27.
6
Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma.
Br J Surg. 2016 Feb;103(3):179-91. doi: 10.1002/bjs.9969. Epub 2015 Dec 10.
7
Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4. doi: 10.1097/SLA.0000000000001441.
8
Approach to patients with pancreatic cancer without detectable metastases.
J Clin Oncol. 2015 Jun 1;33(16):1770-8. doi: 10.1200/JCO.2014.59.7930. Epub 2015 Apr 27.
9
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Pancreas. 2015 May;44(4):515-21. doi: 10.1097/MPA.0000000000000314.
10
Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Surgery. 2014 Oct;156(4):910-20. doi: 10.1016/j.surg.2014.06.058.
Zotero 插件